Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer: An Eastern Cooperative Oncology Group study

J. L. Clark, O. Kucuk*, D. S. Neuberg, A. B. Benson, S. G. Taylor IV, K. J. Pandya, E. G. Mansour, H. O. Douglass, D. G. Haller

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations


A phase II study was performed to determine the efficacy and toxicity of the etoposide, doxorubicin, cisplatin (EAP) regimen in the treatment of patients with advanced measurable gastric cancer in a multi-institutional cooperative group setting. Thirty-one evaluable patients with advanced measurable gastric adenocarcinoma were treated with etoposide 120 mg/m2 on days 3, 4, and 5, doxorubicin 20 mg/m2 on days 1 and 8, and cisplatin 40 mg/m2 on days 2 and 9. The treatment was repeated every 28 days. Objective responses were seen in 7 (23%) patients, all achieving partial remissions. Median survival was 9 months for the entire group. Toxicity was mostly hematologic, with grade 3 leukopenia in 26% and grade 4 leukopenia in 55% of the patients. There were 4 treatment-related deaths that were attributable to severe leukopenia and sepsis. Because of the high toxicity and moderate response rate, this regimen is not superior to other less toxic regimens and cannot be recommended for the treatment of advanced gastric cancer outside of an investigational protocol.

Original languageEnglish (US)
Pages (from-to)318-324
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number4
StatePublished - Jan 1 1995



  • Advanced gastric cancer
  • Cisplatin
  • Combination chemotherapy
  • Doxorubicin
  • Etoposide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this